Quetiapine (Seroquel) Can Be Continued During ECT With Appropriate Monitoring
Quetiapine is not absolutely contraindicated with ECT and can be safely continued with appropriate monitoring, though ideally ECT should be administered without concurrent medications when clinically possible. 1
Key Guideline Recommendations
The American Academy of Child and Adolescent Psychiatry practice parameters clearly state that "there is no consensus on which psychotropic medications, if any, are absolutely contraindicated with concurrent ECT" 1. The guidelines specifically identify problematic medications (lithium, trazodone, carbamazepine, theophylline, and benzodiazepines) but quetiapine is notably absent from this list 1.
The Guideline Framework:
- First-line approach: Whenever clinically possible, administer ECT without concurrent medications 1
- When medications are necessary: They may be administered with appropriate monitoring 1
- Specific concerns to monitor: Seizure threshold alterations and prolonged seizures 1
Evidence Supporting Quetiapine Safety
Recent research directly addresses this question. A 2024 study examining 104 depressive patients found that concomitant antipsychotic medication (including quetiapine) during ECT did not reduce effectiveness and did not increase seizure duration risk 2. The study specifically examined quetiapine augmentation and concluded that "this combination therapy is safe and effective" 2.
Important Nuance - One Case Report:
There is a single 2015 case report of serotonin syndrome after ECT in a patient on quetiapine combined with trazodone and bupropion 3. However, this occurred with multiple serotonergic agents, and the syndrome did not recur when ECT continued with different medications 3. This suggests the issue was polypharmacy-related rather than quetiapine-specific.
Clinical Decision Algorithm
Step 1: Assess Clinical Necessity
- Is the patient's psychiatric condition stable enough to discontinue quetiapine temporarily?
- Would discontinuation risk clinical deterioration that outweighs theoretical ECT interaction risks?
Step 2: If Continuing Quetiapine:
- Monitor seizure duration during each ECT session (should be 30-90 seconds) 1
- Watch for prolonged seizures (>180 seconds) 1
- Have methohexital, diazepam, or lorazepam available to terminate prolonged seizures 1
- Monitor for 24-48 hours post-ECT for tardive seizures 1
Step 3: Avoid Problematic Combinations
- Do NOT combine with multiple serotonergic agents (risk of serotonin syndrome) 3
- Be cautious with QT-prolonging medications, as quetiapine can prolong QTc 4
Common Pitfalls to Avoid
Don't automatically discontinue all psychotropics: The evidence shows quetiapine can be safely continued 2, 5
Don't ignore the FDA label warnings about QT prolongation: While quetiapine wasn't associated with persistent QT increases in clinical trials, post-marketing cases exist 4. Check baseline QTc and avoid other QT-prolonging drugs.
Don't confuse quetiapine with the specifically problematic medications: Lithium (acute brain syndrome risk), trazodone (prolonged seizures), carbamazepine (seizure induction failure), and benzodiazepines (increased seizure threshold) are the documented concerns 1. Quetiapine is not in this category.
Don't rely on quetiapine as a sedative adjunct: Recent evidence shows quetiapine does not reduce sedative requirements in ICU settings 6, so don't use it primarily for sedation during ECT.
Practical Monitoring Protocol
- Baseline: QTc, seizure history, current medication list
- During ECT: EEG monitoring of seizure duration, vital signs
- Post-ECT: Recovery monitoring for 1-2 hours, then 24-48 hour observation for tardive seizures 1
- Between sessions: Assess for cognitive effects, mood changes, or emergence of mania 1
The bottom line: Quetiapine continuation during ECT is supported by both guideline recommendations and recent research, provided appropriate seizure monitoring is in place and polypharmacy with other serotonergic agents is avoided.